Mannitol 15 % w/v Viaflo inf. opl. i.v. Belgia - nederlandsk - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

mannitol 15 % w/v viaflo inf. opl. i.v.

baxter sa-nv - mannitol 15 g/100 ml - oplossing voor infusie - mannitol 150 mg/ml - mannitol

Mannitol 15 % w/v Viaflo sol. perf. i.v. Belgia - fransk - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

mannitol 15 % w/v viaflo sol. perf. i.v.

baxter sa-nv - mannitol 15 g/100 ml - solution pour perfusion - mannitol 150 mg/ml - mannitol

Mannitol 15 % w/v Viaflo inf. opl. i.v. Belgia - nederlandsk - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

mannitol 15 % w/v viaflo inf. opl. i.v.

baxter sa-nv - mannitol 15 g/100 ml - oplossing voor infusie - mannitol

Mannitol 15 % w/v Viaflo inf. opl. i.v. Belgia - nederlandsk - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

mannitol 15 % w/v viaflo inf. opl. i.v.

baxter sa-nv - mannitol 15 g/100 ml - oplossing voor infusie - mannitol

Mannitol 15 % w/v Viaflo sol. perf. i.v. Belgia - fransk - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

mannitol 15 % w/v viaflo sol. perf. i.v.

baxter sa-nv - mannitol 15 g/100 ml - solution pour perfusion - mannitol

Mannitol 15 % w/v Viaflo sol. perf. i.v. Belgia - fransk - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

mannitol 15 % w/v viaflo sol. perf. i.v.

baxter sa-nv - mannitol 15 g/100 ml - solution pour perfusion - mannitol

Mannitol 15 % w/v Viaflo inf. sol. i.v. Belgia - engelsk - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

mannitol 15 % w/v viaflo inf. sol. i.v.

baxter sa-nv - mannitol 15 g/100 ml - solution for infusion - mannitol 150 mg/ml - mannitol

MANNITOL injection, solution USA - engelsk - NLM (National Library of Medicine)

mannitol injection, solution

general injectables & vaccines, inc - mannitol (unii: 3owl53l36a) (mannitol - unii:3owl53l36a) - mannitol 250 mg in 1 ml - mannitol injection is indicated for the reduction of: - intracranial pressure and treatment of cerebral edema. - elevated intraocular pressure. mannitol injection is contraindicated in patients with: - known hypersensitivity to mannitol [see warnings and precautions (5.1)]. - anuria [see warnings and precautions (5.2)]. - severe hypovolemia [see warnings and precautions (5.4)]. - pre-existing severe pulmonary vascular congestion or pulmonary edema [see warnings and precautions (5.5)]. - active intracranial bleeding except during craniotomy. 8.1 pregnancy risk summary the available case report data with mannitol over decades of use have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. mannitol crosses the placenta and may cause fluid shifts that could potentially result in adverse effects in the fetus (see data).no adverse developmental effects from mannitol were reported in published animal studies; however, fluid shifts occurred in fetal ewes i

MANNITOL injection, solution USA - engelsk - NLM (National Library of Medicine)

mannitol injection, solution

b. braun medical inc. - mannitol (unii: 3owl53l36a) (mannitol - unii:3owl53l36a) - mannitol 20 g in 100 ml - mannitol injection is indicated for: - reduction of intracranial pressure and treatment of cerebral edema. - reduction of elevated intraocular pressure. mannitol injection is contraindicated in patients with: - hypersensitivity to mannitol [see warnings and precautions (5.1)] - anuria [see warnings and precautions (5.2)] - severe hypovolemia [see warnings and precautions (5.4)] - pre-existing severe pulmonary vascular congestion or pulmonary edema [see warnings and precautions (5.5)] -   active intracranial bleeding except during craniotomy. the available case report data with mannitol over decades of use have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes.  mannitol crosses the placenta and may cause fluid shifts that could potentially result in adverse effects in the fetus (see data) .  no adverse developmental effects from mannitol were reported in published animal studies; however, fluid shifts occurred in fetal ewes in response to maternal

MANNITOL injection, solution USA - engelsk - NLM (National Library of Medicine)

mannitol injection, solution

hospira, inc. - mannitol (unii: 3owl53l36a) (mannitol - unii:3owl53l36a) - mannitol 5 g in 100 ml - mannitol injection is indicated for the reduction of: - intracranial pressure and treatment of cerebral edema. - elevated intraocular pressure. mannitol injection is contraindicated in patients with: - known hypersensitivity to mannitol [see warnings and precautions (5.1)]. - anuria [see warnings and precautions (5.2)]. - severe hypovolemia [see warnings and precautions (5.4)]. - pre-existing severe pulmonary vascular congestion or pulmonary edema [see warnings and precautions (5.5)] . - active intracranial bleeding except during craniotomy. risk summary the available case report data with mannitol over decades of use have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. mannitol crosses the placenta and may cause fluid shifts that could potentially result in adverse effects in the fetus (see data) .no adverse developmental effects from mannitol were reported in published animal studies; however, fluid shifts occurred in fetal ewes in resp